Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

UNLABELLED Despite gains in survival, outcomes for patients with metastatic or recurrent rhabdomyosarcoma remain dismal. In a collaboration between the National Cancer Institute, Children's Oncology Group, and Broad Institute, we performed whole-genome, whole-exome, and transcriptome sequencing to characterize the landscape of somatic alterations in 147 tumor/normal pairs. Two genotypes are evident in rhabdomyosarcoma tumors: those characterized by the PAX3 or PAX7 fusion and those that lack these fusions but harbor mutations in key signaling pathways. The overall burden of somatic mutations in rhabdomyosarcoma is relatively low, especially in tumors that harbor a PAX3/7 gene fusion. In addition to previously reported mutations in NRAS, KRAS, HRAS, FGFR4, PIK3CA, and CTNNB1, we found novel recurrent mutations in FBXW7 and BCOR, providing potential new avenues for therapeutic intervention. Furthermore, alteration of the receptor tyrosine kinase/RAS/PIK3CA axis affects 93% of cases, providing a framework for genomics-directed therapies that might improve outcomes for patients with rhabdomyosarcoma. SIGNIFICANCE This is the most comprehensive genomic analysis of rhabdomyosarcoma to date. Despite a relatively low mutation rate, multiple genes were recurrently altered, including NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1, FBXW7, and BCOR. In addition, a majority of rhabdomyosarcoma tumors alter the receptor tyrosine kinase/RAS/PIK3CA axis, providing an opportunity for genomics-guided intervention.

[1]  James R. Anderson,et al.  PAX‐FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report , 2013, Pediatric blood & cancer.

[2]  Khin Thway,et al.  Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo , 2013, Clinical Cancer Research.

[3]  C. Berking,et al.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.

[4]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[5]  D. Hawkins,et al.  Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies , 2012, Pediatric blood & cancer.

[6]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[7]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[8]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[9]  Jessica C. Ebert,et al.  Computational Techniques for Human Genome Resequencing Using Mated Gapped Reads , 2012, J. Comput. Biol..

[10]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[11]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[12]  R. Arceci.  PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification , 2012 .

[13]  P. D. Rijk,et al.  Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing , 2011, Nature Biotechnology.

[14]  G. Grosveld,et al.  PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. , 2011, Cancer research.

[15]  L. Borsu,et al.  Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways , 2011, Clinical Cancer Research.

[16]  L. Pasqualucci,et al.  Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. , 2011, Blood.

[17]  S. Salzberg,et al.  TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.

[18]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[19]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[20]  S. Cameron,et al.  High‐resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis , 2011, Genes, chromosomes & cancer.

[21]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[22]  Süleyman Cenk Sahinalp,et al.  deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data , 2011, PLoS Comput. Biol..

[23]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[24]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[25]  Lynette M. Smith,et al.  Genomic and Clinical Analysis of Amplification of the 13q31 Chromosomal Region in Alveolar Rhabdomyosarcoma: A Report from the Children's Oncology Group , 2011, Clinical Cancer Research.

[26]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[27]  G. Grosveld,et al.  PAX 3-FOXO 1 Induces Cannabinoid Receptor 1 to Enhance Cell Invasion and Metastasis , 2011 .

[28]  P. Meltzer,et al.  Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. , 2011, Cancer research.

[29]  J. Licht,et al.  Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo , 2010, BMC Genomics.

[30]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[31]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[32]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[33]  Robert B. Hartlage,et al.  This PDF file includes: Materials and Methods , 2009 .

[34]  W. Krzyzosiak,et al.  Sequence-non-specific effects of RNA interference triggers and microRNA regulators , 2009, Nucleic acids research.

[35]  R. Arceci.  Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma , 2010 .

[36]  S. Nelson,et al.  BFAST: An Alignment Tool for Large Scale Genome Resequencing , 2009, PloS one.

[37]  L. Staudt,et al.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. , 2009, The Journal of clinical investigation.

[38]  C. Dominici,et al.  RAS signaling dysregulation in human embryonal Rhabdomyosarcoma , 2009, Genes, chromosomes & cancer.

[39]  S. Ognjanovic,et al.  Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005 , 2009, Cancer.

[40]  Lynette M. Smith,et al.  Genomic and clinical analyses of 2p24 and 12q13‐q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group , 2009, Genes, chromosomes & cancer.

[41]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[42]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[43]  C. Linardic.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma. , 2008, Cancer letters.

[44]  H. Xiang,et al.  Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma , 2007, Modern Pathology.

[45]  J. Herndon,et al.  The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. , 2007, Cancer research.

[46]  Gabriel S. Eichler,et al.  Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. , 2007, Cancer research.

[47]  J. A. Wamstad,et al.  Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets , 2006, Molecular and Cellular Biology.

[48]  Christian J Stoeckert,et al.  STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. , 2006, Genome research.

[49]  T. Triche,et al.  Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. , 2006, Cancer research.

[50]  Y. Hayashi,et al.  Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies , 2006, Genes, chromosomes & cancer.

[51]  R. Arceci,et al.  Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1 , 2006 .

[52]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Benjamin R. Arenkiel,et al.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. , 2004, Genes & development.

[54]  田中 佐.  Research article , 2000, Hydrobiologia.

[55]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  G. Grosveld,et al.  Pax3-FKHR Knock-In Mice Show Developmental Aberrations but Do Not Develop Tumors , 2002, Molecular and Cellular Biology.

[57]  P. Sorensen,et al.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  P. Sorensen,et al.  Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes , 2002, Genes, chromosomes & cancer.

[59]  P. Houghton,et al.  P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. , 2000, Medical and pediatric oncology.

[60]  E. Verdin,et al.  BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.

[61]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[62]  M. Bittner,et al.  Elucidation of the Downstream Targets of the PAX3-FKHR Fusion Oncogene Found in Aveolar Rhabdomyosarcoma Using cDNA Microarrays , 1999 .

[63]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[64]  G. Basso,et al.  Analysis of cyclin‐dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma , 1996, Genes, chromosomes & cancer.

[65]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[66]  J. Biegel,et al.  Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. , 1994, Cancer research.

[67]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐II , 1993, Cancer.

[68]  J. Biegel,et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[69]  M. Stratton,et al.  Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. , 1989, Cancer research.

[70]  C. Sapienza,et al.  A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting , 1989 .

[71]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.